Plaintiff alleges that on July 22, 2025, Replimune announced that it had received a complete response letter ("CRL") from the FDA for RPI Biologics License Application for the treatment of advanced melanoma and that the CRL "indicates that the FDA is unable to approve the application in its present form because the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness. On this news, the price of Replimune stock plummet ...